Screening method
AssigneeIsis Innovation Limited
InventorsNicholas B. La Thangue, Susan Fotheringham
Life of this patent
Estimating the term…
Abstract
This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.
Claims22
A method for identifying a candidate biomarker that correlates with sensitivity of a disease to a drug that kills tumour cells, the method comprising;
- a) exposing a tumour cell to:
- i) the drug at a concentration capable of killing all the tumour cells;
- ii) a compound which inhibits the level or activity of a protein in the cell;
- b) monitoring for survival of the cell or cells;
- wherein if the cell survives despite the presence of the drug, the protein or its encoding gene is identified as a candidate biomarker that correlates with drug sensitivity.
A method for identifying a candidate biomarker that correlates with the sensitivity of a disease to a drug, the method comprising:
- a) exposing a cell to:
- i) the drug;
- ii) a compound which inhibits the level or activity of a protein in the cell;
- b) monitoring for survival of the cell or cells;
- wherein the outcome of treatment with the drug alone is apoptosis of all cells, and
- wherein if the cell survives despite the presence of the drug, the protein or its encoding gene is identified as a candidate biomarker that correlates with drug sensitivity.
Dependencies are inferred from the claim text.